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Background
The V3 loop of gp120 was identified as the ''principle neu-
tralizing domain'' of HIV-1, but because of its high
sequence variability, V3 has been considered an inappro-
priate target for vaccines. However, V3 is a part of the Env
that interacts with the chemokine receptors and therefore,
despite its sequence variation, must retain conserved
structural features. Nevertheless, the ability of anti-V3
antibodies to neutralize diverse HIV-1 isolates from differ-
ent subtypes has remained in question.
Methods
HIV neutralization experiments were conducted in two
independent labs to test seven anti-V3 monoclonal anti-
bodies (mAbs) against a total of 98 pseudoviruses (psVs)
expressing Env of HIV-1 subtypes A, B, C, D, and AG from
acute and chronic patients. MAbs against parvovirus or
anthrax antigens were used as negative controls. Statisti-
cally significant neutralization was determined based on
evaluation of the area under the titration curve (AUC).
Results
Statistically significant neutralization (p < 0.001) was
detected with each anti-V3 mAb against 26-35% of psVs
but not with the irrelevant mAb controls. For many mAb/
psV combinations, 50% neutralization was not attained at
the highest mAb concentration tested (50 μg/ml),
although dose-response relationships were demonstrated
by the neutralization curves, and the AUC values were sig-
nificantly above background. All seven mAbs showed sta-
tistically significant neutralizing activities against psVs
carrying Envs of all subtypes tested. As many as 63% and
45% of psVs with subtypes B and C Envs had significant
neutralization activity, respectively, by at least one anti-V3
mAb, although among psVs with Env of subtypes A and D,
only one or two in each subtype (10-20%) were sensitive
to the anti-V3 mAbs. Overall, 52 (53%) of 98 psVs
showed significant neutralization activity against one or
more anti-V3 mAbs.
Conclusion
While the neutralization potency of individual anti-V3
mAbs is generally low, anti-V3 mAbs display both intra-
and inter-subtype neutralizing activities.
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